证券代码：603259 证券简称：药明康德 公告编号：临 2025-005 无锡药明康德新药开发股份有限公司 第三届董事会第十七次会议暨 2024 年年度董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 3 月 3 日及 2025 年 3 月 14 日向本公司全体董事发出会议通知及会议材 料，以现场结合通讯表决方式于 2025 年 3 月 17 日在公司会议室召开第三届董事 会第十七次会议暨 2024 年年度董事会会议。本次董事会会议应出席董事 12 人， 实际出席董事 12 人，会议由董事长 Ge Li（李革）主持。本次董事会符合《中华 人民共和国公司法》（以下简称"《公司法》"）和《无锡药明康德新药开发股 份有限公司章程》（以下简称"《公司章程》"）关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于 2024 年度董事会工作报告的议案》 同意《无锡药明康德新药开发股份有限公司 2 ...

Financial Performance - Total revenue for 2024 was approximately CNY 39.24 billion, a decrease of 2.73% compared to CNY 40.34 billion in 2023 [25]. - Net profit attributable to shareholders for 2024 was approximately CNY 9.45 billion, down 1.63% from CNY 9.61 billion in 2023 [25]. - The net profit after deducting non-recurring gains and losses was approximately CNY 9.99 billion, an increase of 2.47% from CNY 9.75 billion in 2023 [25]. - The company's total assets increased by 9.04% to approximately CNY 80.33 billion at the end of 2024, compared to CNY 73.67 billion at the end of 2023 [25]. - The net assets attributable to shareholders increased by 6.37% to approximately CNY 58.63 billion at the end of 2024, compared to CNY 55.12 billion at the end of 2023 [25]. - Basic earnings per share for 2024 were CNY 3.28, a slight increase of 0.31% from CNY 3.27 in 2023 [26]. - The weighted average return on equity decreased to 16.78% in 2024, down 2.21 percentage points from 18.99% in 2023 [26]. - The net cash flow from operating activities for 2024 was approximately CNY 12.41 billion, a decrease of 7.32% from CNY 13.39 billion in 2023 [25]. - The company reported a total revenue of RMB 39.24 billion, a decrease of 2.73% compared to the previous year, with a gross profit of RMB 16.28 billion and a gross margin of 41.48% [52]. Dividend and Profit Distribution - The proposed cash dividend for the 2024 fiscal year is RMB 9.8169 per 10 shares, totaling RMB 2,835,113,437.82, which represents 30.00% of the net profit attributable to shareholders [6]. - The total amount for cash dividends and share repurchase is RMB 5,835,115,356.69, accounting for 61.75% of the net profit attributable to shareholders for the year [6]. - The average net profit over the last three accounting years was RMB 9,290,256,865.45, resulting in a cash dividend ratio of 122.35% [161]. - The company’s cash dividend policy aims to ensure a stable and sustainable return to investors, with a minimum cash distribution of 10% of the distributable profit for the year [154]. - The proposed profit distribution plan is subject to approval at the company’s shareholders' meeting [156]. - The company has maintained a positive profit distribution strategy, ensuring that cash dividends are aligned with its long-term development goals [154]. Market Expansion and Growth Strategy - The company plans to continue expanding its market presence and investing in new technologies and products to drive future growth [27]. - The company expects revenue from continuing operations to return to double-digit growth in 2025, with a year-on-year increase of 10%-15%, reaching RMB 41.5-43 billion [48]. - WuXi AppTec plans to expand its market presence in Europe, targeting a 30% increase in revenue from this region by 2025 [120]. - The company is investing RMB 1 billion in new product development, focusing on biologics and gene therapy technologies [120]. - The company is exploring potential acquisitions to enhance its service offerings, with a budget of $300 million allocated for this purpose [122]. Client and Order Growth - The company had approximately 6,000 active clients at the end of 2024, with 5,500 in ongoing operations and 1,000 new clients added during the year, reflecting a growing demand for services globally [36]. - The total orders in hand for ongoing operations reached RMB 49.31 billion, representing a year-on-year increase of 47.0% [36]. - Revenue from the top 20 global pharmaceutical companies amounted to RMB 16.64 billion, with a year-on-year growth of 24.1% after excluding specific commercial production projects [39]. - User data indicated a 25% increase in the number of active clients, totaling 1,500 clients by the end of 2024 [120]. Research and Development - The company’s R&D expenses decreased by 14.03% to RMB 1.24 billion, while investment income surged by 158.36% to RMB 604 million [51]. - Research and development expenses accounted for 10% of total revenue, amounting to RMB 2 billion in 2024 [120]. - The company has a total of 31,819 R&D personnel, accounting for 80.7% of the total workforce [64]. - The company has launched three new service platforms aimed at improving client engagement and operational efficiency [120]. Environmental Responsibility - The company invested approximately 17.03 million yuan in environmental protection during the reporting period [170]. - The company has established a waste management program to ensure compliance with national regulations, with hazardous waste being handled by qualified third-party companies [187]. - The company is committed to continuous improvement in environmental performance, as evidenced by its comprehensive reporting and management of emissions and waste [172]. - The company reported a total of 9.945 tons of COD emissions from wastewater discharge, with a concentration range of 23-70 mg/L, well below the limit of 500 mg/L [172]. Governance and Compliance - The company has established a robust internal control system to ensure compliance with national laws and regulations, although risks remain due to the number of subsidiaries [100]. - The company has maintained a fully independent operational capability, with no business dependencies or competitive relationships with enterprises controlled by the actual controller [113]. - The company has implemented a comprehensive human resources management system, ensuring that all directors and senior management are elected or appointed through legal procedures, with no interference from the controlling shareholder [112]. - The company has not faced any penalties from securities regulatory agencies in the past three years [132]. Financial Health and Stability - The company’s cash and cash equivalents increased to ¥18.32 billion, representing 22.81% of total assets, up from 18.68% in the previous period, reflecting a growth of 33.12% [70]. - The company reported a significant reduction in short-term borrowings, decreasing by 66.11% to ¥1.24 billion, down from ¥3.67 billion in the previous period [70]. - The total assets of the company increased by 10% to 15 billion RMB, indicating strong financial health and stability [124]. - The company’s long-term borrowings increased by 330.78% to ¥2.96 billion, compared to ¥687.02 million in the previous period [70].

关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2024 年度利润分配方案，每 10 股派发现金红利人民币 9.8169 元（含税）。 此次利润分配方案以 2024 年度实施权益分派股权登记日的总股本为基 数，具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日前公司 总股本发生变动的，按照每股分配金额不变的原则进行分配，相应调整分配总额， 并将另行公告具体调整情况。 此次利润分配方案未触及《上海证券交易所股票上市规则》（以下简称 "《股票上市规则》"）第 9.8.1 条第一款第（八）项规定的可能被实施其他风 险警示的情形。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-007 无锡药明康德新药开发股份有限公司 一、利润分配方案内容 （一）2024 年度利润分配方案的具体内容 经德勤华永会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）2024 年度实现 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 分配方案：每 10 股派发现金红利人民币 3.5000 元（含税）。 此次回报股东特别分红方案以实施此次权益分派股权登记日的总股本 为基数，具体日期将在权益分派实施公告中明确。在实施权益分派股权登记日前 公司总股本发生变动的，按照每股分配金额不变的原则进行分配，相应调整分配 总额，并将另行公告具体调整情况。 一、特别分红方案 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2024 年 12 月 25 日公告通过其全资子公司 WuXi ATU (Ireland) Holding Limited、 WuXi ATU (Hong Kong) Limited 向 Altaris LLC（包括其所控制的主体）转让 WuXi ATU 业务的美国及英国运营主体的全部股权，并于 2025 年 3 月 7 日（美国时间） 完成交割。该部分业务的出售主要是为了确保所有迫切需要 WuXi ATU 细胞治 疗服务的客户和患者得到不受中断的服务和及时救治，同时 WuX ...

无锡药明康德新药开发股份有限公司 关于提请股东大会授权董事会制定中期分红方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"）根据《中华人民 共和国公司法》《上市公司章程指引》《上市公司监管指引第 3 号——上市公司 现金分红》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等相 关法律、法规、规范性文件及《无锡药明康德新药开发股份有限公司章程》规定， 为进一步提高分红频次，增强投资者回报水平，结合公司实际情况，公司董事会 提请股东大会授权董事会，在授权范围内制定并实施公司 2025 年中期分红方案， 具体安排如下： 一、2025 年中期现金分红安排 1、中期分红的前提条件为： （1）公司在当期盈利、累计未分配利润为正；（2）公司现金流可以满足正 常经营和持续发展的要求。 证券代码：603259 证券简称：药明康德 公告编号：临 2025-009 1 公司于 2025 年 3 月 17 日召开第三届董事会第十七次会议暨 2024 年年度董 事会会议和第三届监 ...

Summary of WuXi's FY24 Preview and Outlook Industry Overview - **Industry**: China Healthcare, specifically focusing on the CRO/CDMO (Contract Research Organization/Contract Development and Manufacturing Organization) sector - **Key Players**: WuXi AppTec, WuXi Biologics, WuXi XDC Core Insights and Arguments 1. **Valuation Recovery**: Current valuations do not adequately reflect positive trends such as early-stage demand recovery, bottoming prices, and growth in new modalities. WuXi's results and backlog growth are critical indicators of an industry uptrend [1][2][20] 2. **Biosecure Act Impact**: The Biosecure Act's year-long debate has concluded, stabilizing the average FY2 P/E for the CRO/CDMO segment at 20x, close to pre-Biosecure levels. Structural factors are becoming more favorable, including a resurgence in drug R&D demand and increased capacity utilization [2][3][20] 3. **Geopolitical Risks**: WuXi's market share stability is questioned amid geopolitical risks, including tariffs and potential future iterations of the Biosecure Act. However, the year-long debate has allowed for a more rational assessment of WuXi's role in the global drug supply chain [3][19] 4. **Stock Preferences**: WuXi XDC is favored due to its lower geopolitical exposure and strong market share in outsourced bioconjugates. WuXi AppTec is well-positioned to benefit from GLP-1 outsourcing demand, while WuXi Bio has secured a significant number of new projects despite regulatory challenges [4][26][34] Financial Performance and Projections 1. **Earnings Guidance**: WuXi AppTec is projected to see modest revenue growth in 2025, with a backlog growth likely to surprise positively. WuXi Biologics is expected to maintain in-line performance, while WuXi XDC anticipates significant upside due to backlog growth and capital expenditure announcements [9][24] 2. **Revenue Growth**: WuXi AppTec's revenue is expected to decline slightly in 2024 but rebound in 2025, while WuXi Bio anticipates 5-10% revenue growth. WuXi XDC is projected to achieve over 85% revenue growth in 2024 [24][32][34] 3. **Valuation Metrics**: WuXi AppTec is trading at a P/E of 15x-16x for 2025, while WuXi Bio is at 21x. WuXi XDC's valuation is at 30x, which is considered undemanding given its projected earnings growth [28][33][37] Emerging Trends and Opportunities 1. **New Modalities**: The development of emerging modalities such as ADCs (Antibody-Drug Conjugates) and GLP-1 peptides is driving demand. WuXi's capabilities in these areas position it well for future growth [2][34] 2. **Global Expansion**: WuXi is focusing on overseas capacity expansion to mitigate geopolitical risks and enhance profitability. The company aims for a balanced revenue contribution between China and international markets by 2030 [3][31][19] 3. **Market Leadership**: WuXi AppTec's leadership in small molecule chemical synthesis is reinforced by its ability to adapt to complex demands and competitive pricing, while WuXi Bio is leveraging its CRDMO model to manage risks in biologics outsourcing [26][29] Important Considerations 1. **Investor Sentiment**: Despite positive earnings growth prospects, investor concerns remain regarding the potential re-emergence of the Biosecure Act and its implications for stock performance [18][19] 2. **Profitability and Capex**: The level of profitability from overseas facilities and the capital expenditure plans are crucial factors to monitor as WuXi navigates its global dual-sourcing strategy [19][20] This comprehensive analysis highlights the potential for growth within WuXi and the broader CRO/CDMO sector, while also acknowledging the challenges posed by geopolitical factors and regulatory uncertainties.

证券代码：603259 证券简称：药明康德 公告编号：临 2025-004 无锡药明康德新药开发股份有限公司 关于下属子公司之间提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为确保所有迫切需要 WuXi ATU 细胞治疗服务的客户和患者得到不受中断 的服务和及时救治，同时 WuXiATU 美国和英国业务的相关科学家、技术人员和 其他员工可继续为实现"让天下没有难做的药，难治的病"的使命持续工作，公 司全资子公司 ATU Ireland、ATU HK（即被担保人）与 Altaris LLC（包括其所控 制的主体，以下简称"Altaris"）于 2024 年 12 月 24 日（美国时间）签署《股权 购买协议》（SHARE PURCHASE AGREEMENT），分别将其持有的 WuXi Advanced Therapies Inc.（WuXi ATU 业务的美国运营主体，以下简称"Advanced Therapies"）全部股权及 Oxford Genetics Limited（WuXi ATU ...

呈交日期: 2025年3月3日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 2. 股份分類 | 普通股 | 股份類別 | A | ...

WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 無錫藥明康德新藥開發股份有限公司（「本公司」，連同其子公司「本集團」）董 事會（「董事會」）謹此宣佈將於2025年3月17日（星期一）召開董事會會議，以考 慮及批准（其中包括）本集團截至2024年12月31日止年度全年業績，及建議之末 期股息（如有），以及處理任何其他事項。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 董事會會議召開日期 香港，2025年3月3日 於本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士 及張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞 衛博士、張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 李革博士 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2025年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 387,076,150 | RMB | | 1 | RMB | 387,076,150 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 387,076,150 | RMB | | 1 RMB | | 387,076,150 | | 2. 股份分類 | 普通股 | A 股份類別 | | ...